ANAVEX®3‑71 (AF710B): A Dual-Action Compound for Cognitive Enhancement
ANAVEX®3‑71, previously known as AF710B, is an experimental compound currently in clinical development with powerful nootropic potential. Its unique mechanism of action targets two critical neurological receptors:
Mechanism of Action
-
M1 Muscarinic Receptor Agonism – A key modulator of cognition, learning, and memory.
-
Sigma-1 Receptor Agonism – Linked to neuroprotection, cellular resilience, and anti-inflammatory effects.
Together, these actions may enhance cognitive performance, protect neurons from stress, and potentially address neurodegenerative disorders like Alzheimer’s and schizophrenia.
Dosing Strategy (Based on Clinical Trials)
Clinical data referenced from NCT06245213.
In the trial, dosing was done three times daily (TID).
| Level | Dose Per Day (Divided into 3 doses) |
|---|---|
| Beginner | 15 mg TID (45 mg/day total) |
| Intermediate | 30 mg TID (90 mg/day total) |
| Advanced | 60 mg/day total (as tolerated) |
Caution & Safety
Due to the limited availability of long-term human data, this compound should be approached with care:
-
Start at the lowest effective dose.
-
Monitor for any side effects such as fatigue, dizziness, or mood alterations.
-
Consider cycling the compound and tapering slowly if discontinuing.